CATEGORY: METABOLIC & BLOOD SUGAR
Weight-loss surgery kept blood sugar lower than medicines and lifestyle care for as long as twelve years. That answer comes from a pooled follow-up of four U.S. randomized trials, published in JAMA. At seven years, HbA1c in the surgery group had fallen 1.6 percentage points from a starting average of 8.7%. The medical group’s fell 0.2 points. Diabetes remission reached 18.2% after surgery, against 6.2% with medicines and lifestyle alone.1
Four Small Trials, Followed Farther Downstream
Randomized trials of bariatric surgery have been small and short. These are operations that change the digestive system to treat obesity and the diseases that come with it. Closing that gap was the whole purpose of the ARMMS-T2D project, which pooled four single-center U.S. trials run between 2007 and 2013. Each of those trials had used a random draw to send adults with type 2 diabetes and obesity either to an operation (gastric bypass, sleeve gastrectomy or adjustable banding) or to medical and lifestyle management. Of 305 eligible participants, 262 stayed on for the long follow-up. The median was 11 years. Four small streams, in other words, joined into one river that could be followed much farther downstream.
The Gap Held, and a Quarter of the Medical Group Crossed Over
HbA1c reflects average blood sugar over about three months. Participants entered these trials with poorly controlled diabetes, averaging 8.2% to 8.7%. The distance between the groups was 1.4 percentage points at seven years and 1.1 points at twelve, and the surgery group got there while taking fewer diabetes medications. Remission means blood sugar back in the healthy range with no diabetes medication at all. That described 18.2% of surgical patients at seven years and 6.2% of medical ones. At twelve years it was 12.7% and nobody. The researchers also report a wrinkle plainly: 25% of the people first assigned to medical care eventually had surgery anyway, and everyone was counted in the group they started in. That convention shrinks the measured difference rather than inflating it.
Anemia, Fractures, and Too Few People for Rare Events
The advantage came with a bill. Anemia, a shortage of the red blood cells that carry oxygen, turned up more often after surgery, as did bone fractures and stomach and intestinal complaints. All of that follows from operations that change how food is digested and absorbed. Four participants died over the long years of follow-up, two in each group, and major heart events came out even. With 262 people, the study was too small to settle questions about rare outcomes. Surgery is still a major decision with tradeoffs of its own, and candidacy turns on individual health circumstances that specialists weigh case by case.
A Race Run Before Today’s Diabetes Drugs Existed
These trials began between 2007 and 2013. The most effective current weight-loss and diabetes medicines did not exist yet, so a medical group treated now might close part of the distance. We cannot know that from this data. What the pooled follow-up does show is something no shorter study could: the metabolic benefit was still visible more than a decade on, a durable shift in the course of the disease rather than a temporary dip.
Key Takeaways
- Pooled across four randomized trials, bariatric surgery produced larger and longer-lasting blood sugar improvement than medicines and lifestyle care: 1.4 percentage points of HbA1c at seven years, 1.1 points at twelve, with fewer diabetes medications in use.
- Remission at seven years ran 18.2% after surgery against 6.2% with medical care. At twelve years it was 12.7% versus none.
- Anemia, fractures and digestive side effects were all more common among surgical patients.
- The trials started between 2007 and 2013, so the comparison reflects the diabetes care of that era rather than the newest drugs.
References
- Courcoulas AP, Patti ME, Hu B, et al. Long-Term Outcomes of Medical Management vs Bariatric Surgery in Type 2 Diabetes. JAMA. 2024;331(8):654–664. link